Please use this identifier to cite or link to this item:
Title: Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
Authors: Riley, J. S.
Hutchinson, R.
McArt, D. G.
Crawford, N.
Holohan, C.
Paul, I.
Van Schaeybroeck, S.
Salto-Tellez, M.
Johnston, P. G.
Fennell, Dean A.
Gately, K.
O'Byrne, K.
Cummins, R.
Kay, E.
Hamilton, P.
Stasik, I.
Longley, D. B.
First Published: 5-Dec-2013
Publisher: Nature Publishing Group: Open Access Journals for Associazione Differenziamento e Morte Cellulare
Citation: Cell Death and Disease, 2013, 4, e951
Abstract: Non-small cell lung carcinoma remains by far the leading cause of cancer-related deaths worldwide. Overexpression of FLIP, which blocks the extrinsic apoptotic pathway by inhibiting caspase-8 activation, has been identified in various cancers. We investigated FLIP and procaspase-8 expression in NSCLC and the effect of HDAC inhibitors on FLIP expression, activation of caspase-8 and drug resistance in NSCLC and normal lung cell line models. Immunohistochemical analysis of cytoplasmic and nuclear FLIP and procaspase-8 protein expression was carried out using a novel digital pathology approach. Both FLIP and procaspase-8 were found to be significantly overexpressed in tumours, and importantly, high cytoplasmic expression of FLIP significantly correlated with shorter overall survival. Treatment with HDAC inhibitors targeting HDAC1-3 downregulated FLIP expression predominantly via post-transcriptional mechanisms, and this resulted in death receptor- and caspase-8-dependent apoptosis in NSCLC cells, but not normal lung cells. In addition, HDAC inhibitors synergized with TRAIL and cisplatin in NSCLC cells in a FLIP- and caspase-8-dependent manner. Thus, FLIP and procaspase-8 are overexpressed in NSCLC, and high cytoplasmic FLIP expression is indicative of poor prognosis. Targeting high FLIP expression using HDAC1-3 selective inhibitors such as entinostat to exploit high procaspase-8 expression in NSCLC has promising therapeutic potential, particularly when used in combination with TRAIL receptor-targeted agents.
DOI Link: 10.1038/cddis.2013.481
eISSN: 2041-4889
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © the authors, 2013. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License ( ), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Description: PMCID: PMC3877552
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer..pdfPublished (publisher PDF)1.47 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.